MENU
AIMI
Stock ticker: OTC
PRICE
CHANGE
CAPITALIZATION
AIM ImmunoTech (AIMI) Ownership - Who owns AIM ImmunoTech?
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
5.43M
P/E Ratio
N/A
Total Cash
N/A
Projected Growth
N/A
Total Debt
2.52M
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
N/A
Total Debt/Equity
N/A
Revenue/Share
0.24 USD as % of share price
Fundamentals
AIMI
Capitalization
5.43M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
N/A
Total Cash/Share
N/A
Total Debt
2.52M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.24%
Revenue
N/A
ROE
N/A
Book Value
-3.86M
P/B Ratio
N/A
Cash Flow
N/A
Earnings
N/A
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
72K
Current Ratio
0.26
Current Revenue Per Employee
695.65
Dividends Per Share - Security
N/A
EBITDA
N/A
Float
N/A
Float - Current
N/A
Gross Income Margin
37.50
Revenue To Assets
N/A
Shares Held By Institutions
N/A
Shares Outstanding - Current
764K
Total Liabilities
10.1M
Total Volume MTD
N/A
Value
1
Gain YTD
-64.091
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information